Does a common cholesterol drug make you more likely to get diabetes?
#247 The effect of pravastatin on insulin resistance in patients with CKD stage 1-3. A randomized, placebo-controlled cross over trial
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested if a cholesterol drug called pravastatin affects blood sugar in people with mild kidney problems who don't have diabetes.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 547 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested if a cholesterol drug called pravastatin affects blood sugar in people with mild kidney problems who don't have diabetes.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 547 / 90
Evidence Score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Publication
Related Content
Claims (4)
HMG-CoA reductase inhibition with statins modestly increases the risk of developing type 2 diabetes, particularly in individuals with pre-existing insulin resistance.
Taking pravastatin for 12 weeks didn’t make the body better or worse at using insulin to control blood sugar in people with early-stage kidney disease who don’t have diabetes.
After drinking a sugary solution, people with early kidney disease who took pravastatin had no meaningful difference in their blood sugar two hours later compared to those who took a sugar pill.
Taking pravastatin for 3 months didn’t raise or lower average blood sugar or long-term blood sugar control in people with early kidney disease who don’t have diabetes.